Strs Ohio Takes Position in Integra LifeSciences Holdings Corporation $IART

Key Points

• Strs Ohio has acquired a new stake in Integra LifeSciences Holdings Corporation, purchasing 18,200 shares valued at approximately $400,000 in the 1st quarter.
• The company's recent quarterly earnings report showed an EPS of $0.45, exceeding analysts' estimates, and reported revenue of $415.61 million, which is above the forecast of $395.06 million.
• Integra LifeSciences currently has a market capitalization of $1.12 billion and has seen a volatile share price with a 12-month low of $11.06 and a high of $27.13.

Strs Ohio bought a new stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 18,200 shares of the life sciences company's stock, valued at approximately $400,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Arizona State Retirement System raised its position in shares of Integra LifeSciences by 4.2% in the 1st quarter. Arizona State Retirement System now owns 19,894 shares of the life sciences company's stock valued at $437,000 after buying an additional 795 shares in the last quarter. Envestnet Asset Management Inc. raised its position in shares of Integra LifeSciences by 4.6% in the 1st quarter. Envestnet Asset Management Inc. now owns 27,527 shares of the life sciences company's stock valued at $605,000 after buying an additional 1,204 shares in the last quarter. Sei Investments Co. raised its position in shares of Integra LifeSciences by 7.4% in the 1st quarter. Sei Investments Co. now owns 20,351 shares of the life sciences company's stock valued at $451,000 after buying an additional 1,398 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Integra LifeSciences by 3.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,466 shares of the life sciences company's stock valued at $872,000 after buying an additional 1,437 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Integra LifeSciences by 16.3% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,811 shares of the life sciences company's stock valued at $370,000 after buying an additional 2,357 shares in the last quarter. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Price Performance

Shares of NASDAQ:IART opened at $14.41 on Tuesday. The firm has a 50 day moving average of $13.85 and a 200-day moving average of $15.11. The stock has a market capitalization of $1.12 billion, a PE ratio of -2.21 and a beta of 1.20. The company has a current ratio of 1.23, a quick ratio of 0.73 and a debt-to-equity ratio of 1.18. Integra LifeSciences Holdings Corporation has a 12 month low of $11.06 and a 12 month high of $27.13.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.43 by $0.02. The business had revenue of $415.61 million during the quarter, compared to analysts' expectations of $395.06 million. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. The firm's quarterly revenue was down .6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.63 EPS. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. On average, equities research analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.